Novo Nordisk: By 2025, Novo Nordisk's revenue will grow by 6% to 309.1 billion Danish kroner, with sales in the rare disease field in Greater China increasing by 84% year-on-year based on CER.

2026-02-20 20:07:20

Recently, Novo Nordisk released its full-year 2025 financial report. The company’s sales in 2025 grew by 6% in Danish kroner and by 10% at constant exchange rates, reaching 309.1 billion Danish kroner.

Sales in Greater China increased by 5% at CER (constant exchange rates), mainly driven by sales growth in obesity treatment products. Sales in the rare disease segment in Greater China increased by 84% at CER, primarily driven by sales growth in the rare blood disease field. The China National Medical Products Administration approved Novo Nordisk’s cardiovascular indication for Ozempic based on the SELECT study. Novo Nordisk has submitted data from the SOUL cardiovascular outcomes trial for oral semaglutide in type 2 diabetes patients to update the label for Rybelsus.

The announcement mentioned that at the annual general meeting scheduled for March 26, 2026, the board will propose a dividend of DKK 7.95 per share for the end of 2025, bringing the total dividend for 2025 to DKK 11.70. The board also decided to initiate a new share repurchase program of up to DKK 15 billion.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes